Judith C. Kaiser

971 total citations
10 papers, 306 citations indexed

About

Judith C. Kaiser is a scholar working on Oncology, Pathology and Forensic Medicine and Surgery. According to data from OpenAlex, Judith C. Kaiser has authored 10 papers receiving a total of 306 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 4 papers in Pathology and Forensic Medicine and 3 papers in Surgery. Recurrent topics in Judith C. Kaiser's work include Cancer Immunotherapy and Biomarkers (6 papers), Viral-associated cancers and disorders (3 papers) and Bladder and Urothelial Cancer Treatments (3 papers). Judith C. Kaiser is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Viral-associated cancers and disorders (3 papers) and Bladder and Urothelial Cancer Treatments (3 papers). Judith C. Kaiser collaborates with scholars based in United States, United Kingdom and China. Judith C. Kaiser's co-authors include Martin A. Cheever, Chihiro Morishima, Jeffrey S. Miller, Steven P. Fling, Douglas G. McNeel, Paul M. Sondel, Kevin C. Conlon, Holbrook E. Kohrt, Howard Streicher and Mary L. Disis and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Judith C. Kaiser

9 papers receiving 297 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Judith C. Kaiser United States	4	267	224	31	16	15	10	306
Sami Chu United States	5	276 1.0×	182 0.8×	40 1.3×	8 0.5×	23 1.5×	6	333
Nela Klein-González Germany	7	243 0.9×	209 0.9×	110 3.5×	19 1.2×	16 1.1×	13	344
Paulina Akéus Sweden	8	255 1.0×	144 0.6×	64 2.1×	18 1.1×	24 1.6×	10	329
Javier Celis‐Gutierrez France	5	201 0.8×	114 0.5×	68 2.2×	11 0.7×	10 0.7×	7	254
Ignacio Casas-Avilés Spain	4	205 0.8×	146 0.7×	39 1.3×	6 0.4×	9 0.6×	4	254
Carmine Menna United States	4	284 1.1×	247 1.1×	37 1.2×	7 0.4×	11 0.7×	8	335
Galit Eisenberg Israel	12	193 0.7×	155 0.7×	90 2.9×	35 2.2×	6 0.4×	18	278
Barbara Mosetter Germany	6	160 0.6×	100 0.4×	45 1.5×	34 2.1×	17 1.1×	7	206
Shamin Li United States	7	135 0.5×	83 0.4×	59 1.9×	8 0.5×	9 0.6×	12	196
Marit J van Elsas Netherlands	7	164 0.6×	129 0.6×	54 1.7×	7 0.4×	14 0.9×	8	236

Countries citing papers authored by Judith C. Kaiser

Since Specialization

Citations

This map shows the geographic impact of Judith C. Kaiser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Judith C. Kaiser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Judith C. Kaiser more than expected).

Fields of papers citing papers by Judith C. Kaiser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Judith C. Kaiser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Judith C. Kaiser. The network helps show where Judith C. Kaiser may publish in the future.

Co-authorship network of co-authors of Judith C. Kaiser

This figure shows the co-authorship network connecting the top 25 collaborators of Judith C. Kaiser. A scholar is included among the top collaborators of Judith C. Kaiser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Judith C. Kaiser. Judith C. Kaiser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Ramaswami, Ramya, Angela Shaulov Kask, Leonard D’Amico, et al.. (2025). Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma. Journal for ImmunoTherapy of Cancer. 13(2). e010291–e010291. 2 indexed citations

Sweis, Randy F., Gurkamal Chatta, Helen Moon, et al.. (2024). A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer. Clinical Cancer Research. 31(2). 299–307.

Pachynski, Russell K., Gurkamal Chatta, Rohit Jain, et al.. (2023). 2367P A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) vs. atezo alone in patients with locally advanced or metastatic urothelial carcinoma (mUC). Annals of Oncology. 34. S1204–S1205. 1 indexed citations

Lurain, Kathryn, Ramya Ramaswami, Irene Ekwede, et al.. (2023). 1979P phase I trial of pembrolizumab in HIV-associated Kaposi sarcoma (KS). Annals of Oncology. 34. S1056–S1056. 2 indexed citations

Yu, Evan Y., Steven P. Fling, Bob Salim, et al.. (2019). A randomized phase II study of atezolizumab plus recombinant human IL-7 (CYT107) or atezolizumab alone in patients with locally advanced or metastatic urothelial carcinoma (mUC): A Cancer Immunotherapy Trials Network Trial (CITN-14).. Journal of Clinical Oncology. 37(15_suppl). TPS4586–TPS4586. 2 indexed citations

Uldrick, Thomas S., Priscila Gonçalves, Brinda Emu, et al.. (2019). Phase I study of pembrolizumab in people with HIV and cancer.. Journal of Clinical Oncology. 37(15_suppl). 2500–2500. 3 indexed citations

Margolin, Kim, Chihiro Morishima, Vamsidhar Velcheti, et al.. (2018). Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 24(22). 5552–5561. 146 indexed citations

Slingluff, Craig L., Steven P. Fling, Ileana S. Mauldin, et al.. (2018). Pilot trial of an Indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor plus a multipeptide melanoma vaccine in patients with advanced melanoma.. Journal of Clinical Oncology. 36(15_suppl). 3033–3033. 6 indexed citations

Miller, Jeffrey S., Chihiro Morishima, Douglas G. McNeel, et al.. (2017). A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors. Clinical Cancer Research. 24(7). 1525–1535. 143 indexed citations

10.

Uldrick, Thomas S., Martin A. Cheever, Priscila Gonçalves, et al.. (2017). Interim safety analysis of cancer immunotherapy trials Network – 12 (CITN-12): a Phase 1 study of pembrolizumab in patients with HIV and cancer. Journal of Virus Eradication. 3. 55–56. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact